Calendar

A Science & Innovation Webinar, presented by Pfizer. 

This presentation will discuss LITFULO, ritlecitinib, indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. The program will provide a brief overview of the disease state, consider appropriate patients for oral treatment, review LITFULO’s efficacy and safety profile, and discuss initiation and monitoring of LITFULO.

A Science & Innovation Webinar, presented by Abbvie. 

This webinar will describe the disease states of neurovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR). A brief overview of the current treatment regimens will be presented. Real world data on Anti-VEGF therapy will be examined along with their limitations. An explanation of gene therapy currently under study and the mechanism of action will be provided. A description of the routes of administration for gene therapy in nAMD and DR will be explained.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Otsuka America Pharmaceutical, Inc.

PTSD is a highly prevalent disorder affecting ~13 million US adults in 2022. A potential new treatment was studied in phase 2 and 3 clinical trials to determine its safety and efficacy in treating adult patients with PTSD. This webinar will provide an overview of PTSD and summarize the clinical outcomes observed in these trials.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Abbvie. 

An overview of the impact and burden of Hepatitis C virus in the US, treatment landscape, elimination progress, access restrictions, and the health economics of curative treatment. 

This program will review: 

• Disease state pathophysiology, burden and impact of untreated Hepatitis C in the US. 
• The WHO HCV elimination targets and the progress to date. 
• The current treatment landscape and the AASLD/IDSA guideline recommendations for the treatment of HCV. 
• The current state of access to HCV treatments and the health economics of curative treatment.

A Science & Innovation Webinar, presented by Ascendis.

Addressing gaps in patient care for adults with hypoparathyroidism with reliable treatment beyond conventional therapy.

Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH). PTH is the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidneys and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for approximately 75% of cases, while other etiologies include autoimmune and idiopathic causes.

There is a lack of treatment options for hypoparathyroidism in adults. Conventional therapy consists of oral calcium and active vitamin D, and aims to alleviate hypocalcemia but does not address insufficient parathyroid hormone (PTH). This can lead to a wide range of both short- and long-term complications.
 

A Science & Innovation Webinar, presented by Sanofi. 

The webinar will summarize the clinical efficacy and safety data for Rezurock including reviewing the pivotal study data and product profile of Rezurock.